Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-21-26
I. Vizel’, A. I. Rezyapova, A. Vizel’
In respiratory medicine, the correct inhaler technique determines the clinical efficacy of inhaled medications.
在呼吸医学中，正确的吸入器技术决定了吸入药物的临床疗效。
{"title":"Comparison of the three liquid metered dose inhalers technique in patients with COPD and bronchial asthma","authors":"I. Vizel’, A. I. Rezyapova, A. Vizel’","doi":"10.32756/0869-5490-2023-2-21-26","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-21-26","url":null,"abstract":"In respiratory medicine, the correct inhaler technique determines the clinical efficacy of inhaled medications.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90143748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-32-36
E. Shavarova, E. Khachaturyan, I. Pokatayev, Z. Kobalava
The use of angiogenesis inhibitors (anti-VGEF antibodies and tyrosine kinase inhibitors) in oncology significantly increases both the tumor response to therapy and the risk of cardiovascular toxicity. Arterial hypertension is the main adverse effect of antiangiogenic therapy frequently limiting the doses of angiogenesis inhibitors, although it is also considered as a possible surrogate marker of the effectiveness of targeted therapy. In 2022, the recommendations of the European Society of Cardiology on the prevention and correction of cardiotoxicity of antitumor therapy were published. The article reviews the current diagnosis and treatment of arterial hypertension induced by antiangiogenic medicines.
{"title":"Current diagnosis and treatment of arterial hypertension induced by antiangiogenic antitumour agents","authors":"E. Shavarova, E. Khachaturyan, I. Pokatayev, Z. Kobalava","doi":"10.32756/0869-5490-2023-2-32-36","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-32-36","url":null,"abstract":"The use of angiogenesis inhibitors (anti-VGEF antibodies and tyrosine kinase inhibitors) in oncology significantly increases both the tumor response to therapy and the risk of cardiovascular toxicity. Arterial hypertension is the main adverse effect of antiangiogenic therapy frequently limiting the doses of angiogenesis inhibitors, although it is also considered as a possible surrogate marker of the effectiveness of targeted therapy. In 2022, the recommendations of the European Society of Cardiology on the prevention and correction of cardiotoxicity of antitumor therapy were published. The article reviews the current diagnosis and treatment of arterial hypertension induced by antiangiogenic medicines.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84642697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-37-42
O. S. Davydov
Neuropathic pain caused by disease or damage affecting the somatosensory nervous system is a common problem in the primary care patients. Neuropathic pain can occur in postherpetic neuralgia, Guillain-Barré syndrome, neuroborreliosis, painful diabetic neuropathy, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Sjögren's syndrome, after trauma, due to cancer, stroke, etc. The treatment of neuropathic pain involves a comprehensive multimodal approach using pharmacotherapy with antidepressants and anticonvulsants, the most convenient of which is gabapentin, pathogenetic therapy of the underlying disease and non-pharmacological methods. Only integrated approach can provide effective therapy and improve the quality of life of patients with neuropathic pain.
{"title":"Principles of effective management of neuropathic pain in primary care","authors":"O. S. Davydov","doi":"10.32756/0869-5490-2023-2-37-42","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-37-42","url":null,"abstract":"Neuropathic pain caused by disease or damage affecting the somatosensory nervous system is a common problem in the primary care patients. Neuropathic pain can occur in postherpetic neuralgia, Guillain-Barré syndrome, neuroborreliosis, painful diabetic neuropathy, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Sjögren's syndrome, after trauma, due to cancer, stroke, etc. The treatment of neuropathic pain involves a comprehensive multimodal approach using pharmacotherapy with antidepressants and anticonvulsants, the most convenient of which is gabapentin, pathogenetic therapy of the underlying disease and non-pharmacological methods. Only integrated approach can provide effective therapy and improve the quality of life of patients with neuropathic pain.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84104096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-15-20
S. Gavrisheva, D. Abdurakhmanov, N. Bulanov, E. Tanaschuk, T. Rozina, E. Nikulkina, S. Milovanova, A. Filatova, T. Krasnova, E. Starostina, V. Avdeev, P. Novikov, S. Moiseev
To evaluate the efficacy of direct-acting antivirals (DAA) in patients with hepatitis C virus (HCV) associated cryoglobulinemia and monoclonal gammapathy (MG).
{"title":"Efficacy of direct-acting antivirals in patients with HCV-associated cryoglobulinemia and monoclonal gammapathy","authors":"S. Gavrisheva, D. Abdurakhmanov, N. Bulanov, E. Tanaschuk, T. Rozina, E. Nikulkina, S. Milovanova, A. Filatova, T. Krasnova, E. Starostina, V. Avdeev, P. Novikov, S. Moiseev","doi":"10.32756/0869-5490-2023-2-15-20","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-15-20","url":null,"abstract":"To evaluate the efficacy of direct-acting antivirals (DAA) in patients with hepatitis C virus (HCV) associated cryoglobulinemia and monoclonal gammapathy (MG).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76102065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-66-72
V. Skryabin, A. Masyakin, S. Nazimova, D. Sosin, A. Khannanova, V. Shipitsyn, M. Zastrozhin, D. Sychev
To analyse spontaneous reports (SRs) of adverse drug reactions (ADRs) related to antipsychotics in Russia.
目的分析俄罗斯抗精神病药物不良反应自发性报告(SRs)。
{"title":"Pharmacoepidemiologic study of antipsychotics safety","authors":"V. Skryabin, A. Masyakin, S. Nazimova, D. Sosin, A. Khannanova, V. Shipitsyn, M. Zastrozhin, D. Sychev","doi":"10.32756/0869-5490-2023-2-66-72","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-66-72","url":null,"abstract":"To analyse spontaneous reports (SRs) of adverse drug reactions (ADRs) related to antipsychotics in Russia.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85539918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-43-50
V. Rameev, L. Lysenko (Kozlovskaya), S. Salugina, N. Chebotareva, N. Bulanov, A. Novikov, M. Barsuk, S. Moiseev
Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) belongs to a group of rare hereditary autoinflammatory diseases (familial periodic fevers). TRAPS is characterized by the periodic occurrence of fever, abdominal pain, maculopapular rash, arthralgia/myalgia and laboratory signs of inflammation that persisit for 5 days to 3 weeks. AAamyloidosis can complicate persisting autoinlammation in TRAPS. The authors report two cases of TRAPS and discuss its diagnosis and treatment.
{"title":"Tumour necrosis factor receptor-associated periodic syndrome (TRAPS)","authors":"V. Rameev, L. Lysenko (Kozlovskaya), S. Salugina, N. Chebotareva, N. Bulanov, A. Novikov, M. Barsuk, S. Moiseev","doi":"10.32756/0869-5490-2023-2-43-50","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-43-50","url":null,"abstract":"Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) belongs to a group of rare hereditary autoinflammatory diseases (familial periodic fevers). TRAPS is characterized by the periodic occurrence of fever, abdominal pain, maculopapular rash, arthralgia/myalgia and laboratory signs of inflammation that persisit for 5 days to 3 weeks. AAamyloidosis can complicate persisting autoinlammation in TRAPS. The authors report two cases of TRAPS and discuss its diagnosis and treatment.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81068305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-7-14
Y. Korotchaeva, N. Kozlovskaya, S. Moiseev
Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by uncontrolled complement activation and leading to thrombocytopenia, microangiopathic hemolysis and acute kidney injury. Eculizumab, a humanized monoclonal antibody that inhibits the cleavage of complement protein C5, effectively reverses laboratory evidence of TMA and improves kidney function in most patients with aHUS. Hereditary aHUS should be differentiated from the secondary HUS associated with drugs, autoimmune diseases (e.g. antiphospholipid syndrome), malignancies, infections, solid organ transplantation. Case reports and retrospective studies suggest that eculizumab may be effective in a proportion of patients with secondary TMA, although its efficacy and regimens of administration should be evaluated in additional studies.
{"title":"Complement inhibition therapy in patients with atypical hemolytic uremic syndrome and secondary microangiopathies","authors":"Y. Korotchaeva, N. Kozlovskaya, S. Moiseev","doi":"10.32756/0869-5490-2023-2-7-14","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-7-14","url":null,"abstract":"Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by uncontrolled complement activation and leading to thrombocytopenia, microangiopathic hemolysis and acute kidney injury. Eculizumab, a humanized monoclonal antibody that inhibits the cleavage of complement protein C5, effectively reverses laboratory evidence of TMA and improves kidney function in most patients with aHUS. Hereditary aHUS should be differentiated from the secondary HUS associated with drugs, autoimmune diseases (e.g. antiphospholipid syndrome), malignancies, infections, solid organ transplantation. Case reports and retrospective studies suggest that eculizumab may be effective in a proportion of patients with secondary TMA, although its efficacy and regimens of administration should be evaluated in additional studies.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81896391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Investigation of pharmacokinetics and drug-drug interactions of melatonin and memantine as components of the new original combination drug Miladean®","authors":"A. Goncharov, A. Grigoriev, A. Globenko, I. Goncharov, K. A. Muratov, A. Sidorova, A. A. Nikitin, A. Kapashin, O. Kovchan, A. I. Bashkatova, M. Pasko","doi":"10.32756/0869-5490-2023-2-59-65","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-59-65","url":null,"abstract":"To compare pharmacokinetics and evaluate drug-drug interactions of the studied drug Miladean® oral dispersible tablets 3 mg + 5 mg (JSC Valenta Pharm, Russia) and reference products Akatinol Memantine 10 mg film-coated tablets (Merz Pharma GmbH & Co. KGaA, Germany) and Melaxen 3 mg film-coated tablets (Unipharm Inc., USA).","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91106969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-51-58
A. Zavrazhnova, E. Kuvardin, V. Myachikova, A. Khadgidis, N. Anokhina, M. Anriyanova, Y. Kozlova, A. Maslyanskiy
Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disease mediated by interleukin (IL)-1 production. There are no treatment guidelines for AOSD due to its rarity and heterogenous manifestations. Therefore, each case is challenging and requires a multidisciplinary approach. We report a case of AOSD occurring in pregnant patient who did not respond to standard treatment with glucocorticoids and developed skin reaction to IL-1 receptor antagonist. However, drug desensibilisation was effective and allowed to continue treatment with anakinra.
{"title":"Targeted treatment challenges in patients with adult-onset Still’s disease","authors":"A. Zavrazhnova, E. Kuvardin, V. Myachikova, A. Khadgidis, N. Anokhina, M. Anriyanova, Y. Kozlova, A. Maslyanskiy","doi":"10.32756/0869-5490-2023-2-51-58","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-51-58","url":null,"abstract":"Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disease mediated by interleukin (IL)-1 production. There are no treatment guidelines for AOSD due to its rarity and heterogenous manifestations. Therefore, each case is challenging and requires a multidisciplinary approach. We report a case of AOSD occurring in pregnant patient who did not respond to standard treatment with glucocorticoids and developed skin reaction to IL-1 receptor antagonist. However, drug desensibilisation was effective and allowed to continue treatment with anakinra.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88055762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-21DOI: 10.32756/0869-5490-2023-2-27-31
S. Moiseev, N. Bulanov, A. Moiseev, E. Tao, V. Sholomova, D. Ismailova, E. Mershina
To evaluate clinical features and indications for enzyme replacement therapy (ERT) in female patients with Fabry disease (FD) in the Russian population.
目的评价俄罗斯人群中女性法布里病(FD)患者的临床特点和酶替代治疗(ERT)的适应症。
{"title":"Fabry disease in female patients: clinical features, outcomes and indications for enzyme replacement therapy","authors":"S. Moiseev, N. Bulanov, A. Moiseev, E. Tao, V. Sholomova, D. Ismailova, E. Mershina","doi":"10.32756/0869-5490-2023-2-27-31","DOIUrl":"https://doi.org/10.32756/0869-5490-2023-2-27-31","url":null,"abstract":"To evaluate clinical features and indications for enzyme replacement therapy (ERT) in female patients with Fabry disease (FD) in the Russian population.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"94 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74846244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：